Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Here is the original post:
How Corona Pandemic will Impact Canine Stem Cell Therapy Market Business Opportunity, and Growth 2026 - Cole of Duty

The majority of patients with early stage unfavorable Hodgkin lymphoma respond well enough to a current standard regimen of 4 cycles of chemotherapy, and can skip the additional radiotherapy that is normally included in the combined modality treatment, say experts reporting the final results from an international phase 3 randomized trial dubbed HD17.

"Most patients with this disease will not need radiotherapy any longer," concluded first author Peter Borchmann, MD, assistant medical director in the Department of Hematology/Oncology at the University Hospital of Cologne, Germany.

Borchmann was speaking online as part of the virtual edition of the European Hematology Association (EHA) 25th Annual Congress 2020.

"Importantly, the mortality of patients with early stage unfavorable Hodgkin lymphoma in the HD17 study did not differ from the normal healthy German population, and this is the first time we have had this finding in one of our studies," he emphasized.

Borchmann added that positron emission tomography (PET) imaging is key in deciding which patients can skip radiation.

"We conclude from the HD17 trial that the combined modality concept can and should be replaced by a PET-guided omission of radiotherapy for patients with newly diagnosed early stage unfavorable Hodgkin lymphoma," he said.

"The vast majority of early stage unfavorable Hodgkin lymphoma patients can be treated with the brief and highly effective 2+2 chemotherapy alone," he added.

Therefore, he continued, "PET-guided 2+2 chemotherapy is the new standard of care for the German Hodgkin study group," which conducted the trial.

The use of both chemotherapy and radiation has long been a standard approach to treatment, and this combined modality treatment is highly effective, Borchmann explained. But it can cause long-term damage, and the known longer-term negative effects of radiotherapy, such as cardiovascular disease and second malignancies, are a particular concern because patients with early stage Hodgkin lymphoma are relatively young, with a median age of around 30 years at disease onset.

An expert approached for comment said that the momentum to skip radiotherapy when possible is an ongoing issue, and importantly, this study adds to those efforts.

"The treatment of Hodgkin lymphoma has moved for many years now to less radiation therapy, and this trend will continue with the results of this study," commented John G. Gribben, MD, director of the Stem Cell Transplantation Program and medical director of the North East London Cancer Research Network Centre at Barts Cancer Center of Excellence and The London School of Medicine, UK.

"We have moved to lower doses and involved fields with the intent of decreasing toxicity, and particularly long-termtoxicity from radiotherapy," he told Medscape Medical News.

For the multicenter, phase 3 HD17 trial, Borchmann and colleagues turned to PET to identify patients who had and had not responded well to chemotherapy (PET-negative and PET-positive) and to determine if those who had responded well could safely avoid radiotherapy without compromising efficacy.

We wanted to determine if we could reduce the treatment intensity by omission of radiotherapy in patients who respond very well to the systemic treatment, so who have a complete metabolic remission after the chemotherapy, Borchmann said.

The 2+2 treatment approach includes 2 cycles of eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) and 2 subsequent cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine).

The trial enrolled 1100 patients with newly diagnosed Hodgkin lymphoma between January 2012 and March 2017. Of these, 979 patients had confirmed PET results, with 651 (66.5%) found to be PET-negative, defined as having a Deauville score (DS) of less than 3 (DS3); 238 (24.3%) were DS3 and 90 (9.2%) were DS4.

The study met its primary endpoint of noninferiority in progression-free survival (PFS) at 5 years, with a PFS of 95.1% in the PET-guided group (n = 447) compared with 97.3% in the standard combined-modality treatment group (n = 428), over a median observation time of 45 months, for a difference of 2.2% (P = .12).

"We found that the survival levels were very high and we can safely conclude the noninferiority of the PET-guided approach in PET-negative patients," Borchmann said.

A further analysis showed that the 597 PET-negative patients who did not receive radiotherapy due to their PET status had 5-year PFS that was noninferior to the combined modality group (95.9% vs 97.7%, respectively; P = .20).

And among 646 patients who received the 2+2 regimen plus radiotherapy, of thoseconfirmed as PET-positive (n = 328), the estimated 5-year PFS was significantly lower (94.2%) compared with those determined to be PET-negative (n = 318; 97.6%; hazard ratio, 3.03).

A cut-off of DS4 for positivity was associated with a stronger effect, with a lower estimated 5-year PFS of 81.6% vs 98.8% for DS3 patients and 97.6% for DS < 3 (P < .0001).

"Only DS4 has a prognostic impact, but not DS3," Borchmann said. "DS4 positivity indicates a relevant risk for treatment failure, however, there are few patients in this risk group (9.2% in this trial)."

The 5-year overall survival rates in an intent-to-treat analysis were 98.8% in the standard combined modality group and 98.4% in the PET-guided group.

With a median observation time of 47 months, there have been 10 fatal events in the trial out of 1100 patients, including two Hodgkin lymphoma-related events and one treatment-related death.

"Overall, Hodgkin lymphoma or treatment-related mortality rates were extremely low," Borchmann said.

The study was funded by Deutsche Krebshilfe. Borchmann and Gribben have reported no relevant financial relationships.

EHA 2020 Congress. Presented June 12, 2020. Abstract S101.

For more from Medscape Oncology, join us on Twitter and Facebook.

Read more here:
Safe to Skip Radiotherapy With Negative PET in Hodgkin Lymphoma - Medscape

Stimulating stem cells to heal faster through the use of shock wave therapy is part of the exciting new research by a Canadian veterinarian.

Dr Judith Koenig, a clinician, researcher and instructor at the Ontario Veterinary College (OVC), is investigating whether shock wave therapy performed after injecting stem cells into a tendon will result in better quality healing. Her research team then came up with the idea of pre-treating stem cells with shock wave prior to injection.

Koenig is also leading a clinical trial, currently enrolling thoroughbred racehorses. The trial performs repeated injection of stem cells that have been harvested from umbilical cord blood, frozen and stored in Dr Thomas Kochs lab. These stem cells are from unrelated horses. Funding from the Ontario Equestrian federation has enabled OVC researchers to also follow a control group treated with platelet-rich plasma as a comparison for this study.

Reduced healing time is an obvious benefit to the welfare of the horse and the horse owner will be pleased about a quicker return to their training rgime.

Lameness is a huge focus for Koenig, who is also a rider with a keen interest in helping grassroots riders and upcoming high-performance athletes.

Realizing many will soon be in the position of starting horses back into training after a significant amount of time off, Koenig offers some important advice.

You need to allow at least a six-week training period for the athletes to be slowly brought back and build up muscle mass and cardiovascular fitness, she says. Both stamina and muscle mass need to be retrained.

She stressed the importance in checking the horses legs for heat and swelling before and after every ride and picking out the feet.A good period of walking is required in the warm-up and cool down and riders need to pay attention to soundness in the walk before commencing their work out.

Koenigs main area of interest in research is tissue healing, particularly wound and tendon healing. She has investigated the use of different modalities (for example shockwave or stem cells) to see if they accelerate tissue healing and which cellular pathways are affected. This will help to direct treatment of tendon injuries and wounds in horses.

Koenig is originally from Austria and moved to Canada 1996 after graduating from vet school to gain research experience and complete the research for her MSc. Following a large animal internship at the Ontario Veterinary College she went to Oregon State University where she did a one-year large animal fellowship. The year in Oregon gave her good exposure to Western Pleasure horses as well as Walking horses, which complemented her previous experience with Sports and Racehorse practice.

She came back to the Ontario Veterinary College where she did a three-year large animal surgery residence with a concurrent graduate degree (DVSc). Koenig became board certified with both the American and European College of Veterinary Surgeons and started to work as faculty in Large Animal Surgery in 2003. Since then she has been working half of the time as a surgeon with a strong interest in Equine Sports Medicine and the other half as researcher and teacher. In 2016, Koenig became a board-certified diplomate for equine sports medicine and rehabilitation.

Excerpt from:
Shock wave therapy on stem cells focus of lameness research - Horsetalk

MGD013 is a first-in-class bispecific tetravalent DART molecule designed to bind PD-1 and LAG-3 and restore function of exhausted T cells. Results from a phase 1 study of MGD013 have shown an acceptable safety profile and early activity in patients with advanced solid tumors and hematologic malignancies.

Results of the study were presented by Jason J. Luke, MD, of University of Pittsburgh Hillman Cancer Center in Pennsylvania, during the ASCO20 Virtual Scientific Program.

The study enrolled 50 patients into a dose escalation study from 1 mg to 1200 mg every 2 weeks, and 157 patients into a cohort expansion study at the phase 2 dose of 600 mg.

About 70% of patients experienced a treatment-related adverse event, with 23.2% experiencing grade 3 or worse events. The most commonly reported adverse events were fatigue (19%) and nausea (11%).

Among the patients in the dose escalation cohort who were evaluable for response there were 3 confirmed partial responses. One occurred in a patient with triple-negative breast cancer, 1 in a patient with mesothelioma, and 1 in a patient with gastric cancer. Eighteen patients had stable disease. This resulted in a disease control rate of 48.8%.

Dr Luke note that several cohorts in the study are ongoing, including a lymphoma cohort. He highlighted 1 patient from that cohort, a 27-year-old man with diffuse large B-cell lymphoma who had progression of disease after CAR-T cell therapy. This patient was given a single dose of MGD013 at 600 mg.

A pretreatment biopsy from the patients lymph node showed high expression of PD-1 and LAG-3. After CAR-T, the patient had CD19 loss. After his dose of MGD013, the patient was admitted to the hospital on day 11 due to grade 2 cytokine release syndrome, but had a complete response on PET scan at day 24. The patient later had allogeneic stem cell transplant and is now in remission 11 months post-MGD103.

Evaluation of MGD103 as monotherapy and in combination with FC-engineered monoclonal antibodies such as margetuximab is going, Dr Luke concluded.

Read more of Cancer Therapy Advisors coverage of the ASCO 2020 meeting by visiting the conference page.

Reference

Luke JJ, Patel MR, Hamilton EP, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecular binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms. Presented at: ASCO20 Virtual Scientific Program.J Clin Oncol. 2020;38(suppl):abstr 8001.

Continued here:
Bispecific DART Molecule Targeting PD-1, LAG3 Active, Well-Tolerated - Cancer Therapy Advisor

The Canine Stem Cell Therapy Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Canine Stem Cell Therapy market report covers the worldwide top manufacturers like (VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Canine Stem Cell Therapy market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Canine Stem Cell Therapy Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Canine Stem Cell Therapy[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2081893

Canine Stem Cell Therapy Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Canine Stem Cell Therapy Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Canine Stem Cell Therapy Market Background, 7) Canine Stem Cell Therapy industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Canine Stem Cell Therapy Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Canine Stem Cell Therapy Market:The non-invasive stem cell obtaining procedure, augmented possibility of accomplishing high quality cells, and lower price of therapy coupled with high success rate of positive outcomes have collectively made allogeneic stem cell therapy a preference for veterinary physicians. Moreover, allogeneic stem cell therapy is 100% safe, which further supports its demand on a global level. Pet owners are identified to prefer allogeneic stem cell therapy over autologous therapy, attributed to its relatively lower costs and comparative ease of the entire procedure.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Stem Cells Autologous Stem cells

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2081893

Geographically, the report includes the research on production, consumption, revenue, Canine Stem Cell Therapy market share and growth rate, and forecast (2020-2026) of the following regions:

Important Canine Stem Cell Therapy Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Canine Stem Cell Therapy Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Canine Stem Cell Therapy MarketSummary; MarketScopeGives A BriefOutlineof theCanine Stem Cell Therapy Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Canine Stem Cell Therapy Market.

Canine Stem Cell Therapy Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Canine Stem Cell Therapy market?

To Get Discount of Canine Stem Cell Therapy Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2081893

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

View post:
Coronavirus threat to global Good Growth Opportunities in Canine Stem Cell Therapy Market - Cole of Duty

For millions of Americans, though, keeping normalcy at bay for such a long time is a luxury they cant afford. People need to hold onto their jobs. Or find new ones. The streets are filling up with Americans who are responding to one national crisisthat of police brutality and systemic racismin the midst of another. And the economy is in cardiac arrest.

Just last week, to address this, the governor of my state announced an accelerated reopening. In the last weeks, there were about 1,500 new coronavirus cases in our region, an increase of 37 percent. In all these headlines, I can see cracks in the walls Ive built around my mom and my partner. How do we bubble people stay safe as the world moves ahead? In some ways people who are immunocompromised have lived their lives in preparation for all of this, Mamjunder told me.

Not long ago, in response to WIRED's Covid-19 coverage, the publication got an email from a woman named Brandy Stephens whod been diagnosed with acute lymphoblastic leukemia in 2014, when she was 26. She and her husband had a 1-year-old daughter. Her treatment put her in the hospital for 165 days, 35 of them on a ventilator. During that time a mere houseplant could have killed me, she wrote. I had multi-organ failure, my bone marrow died, I had pulmonary embolisms, a partially collapsed lung. Then, a stem cell transplant built her a new immune system. In July 2019, at the five-year mark, Stephens was finally able to be reimmunized, against the scary things that babies are immunized for.

Most of the world does not know we exist, she wrote.

I called her to ask about how she did it. I needed to know how to shepherd my mom and partner through a reopened world. I couldn't eat takeout for a year post-transplant. I carry sanitizer, gloves, masks, Lysol with me. She added, My husband is my rock. It has become second nature to have real quirks, to, say, go to family gatherings but not get close to anyone. She knows how to do this. I feel for people who never have had to isolate before, she added, I went through that struggle. (Immunocompromised people have figured out how to protest too.)

We are lucky to live in an area that has kept the overall coronavirus numbers low, yet the steady tick of reminders about potential Covid-19 resurgences haunt me. For everyone in this pandemic, its hard right now to accurately see a future beyond quarantine. Will we return to normal this year? What does normal mean? Something different for all of us, of course.

Last Friday afternoon I was working at Moms house, and I took a break. We were sitting in her living room, on her lovely blue couches. The dog tucked his head under her arm. Mom asked me what I was looking forward to.

The question jolted me. In pre-corona times, I tried to keep things on the calendar to look forward to. But over the past two months I have shut that instinct down.

Now, my mind ricocheted. Restaurants. Could I look forward to eating at our favorite pizza joint? My partners brother: He just added a new floor at the top of the house, a big glorious room with sliding glass doors that open to a porch overlooking the Pacific. He wants to have parties in that big, cheerful space. Will we be there?

Here are the things I hope to put on my calendar someday soon: dinner at our friends house. Driving with Mom for a day at our favorite beach, without worrying about crowds. Those parties at my partners brothers house, in that big, cheerful space. And if need be, flights to a different city if the new treatments we need for my partners cancer arrive, via a trial, somewhere else.

I hope I can put all of those things on the calendar, for the time we have left together.

More From WIRED on Covid-19

Read the original post:
The Country Is Reopening. Im Still on Lockdown - WIRED

Health care stakeholders need to invest in value-based care, innovative care delivery models, advanced digital technologies. XploreMR will help you to know declarative, procedural, contextual, and somatic information about the Canine Stem Cell Therapy Market. It also provides a critical assessment of the performance of emerging and mature markets in a new publication titled Global Market Study on Canine Stem Cell Therapy: Ongoing Clinical Trials and Focus on Advancements to Push Adoption in Veterinary Clinics.

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) and many more Information:https://www.xploremr.com/connectus/sample/2360

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

Research Methodology

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Get Full Access Of This Exclusive Report Right Now: https://www.xploremr.com/cart/2360/SL

Standard Report Structure

Target Audience

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Read more:
Canine Stem Cell Therapy Market to Expand with Significant CAGR - WorldsTrend

Many people have found much success with Pet Stem Cell Therapy, and this form of regenerative therapy can be applied to your beloved dogs as well. Stem cell treatments maximize the animals natural healing capabilities, provides relief, and promote overall quality of life. It may be quite the expense, but they have some benefits which cannot be replicated by traditional medicine.

Stem cells are blank slates. They are uncharacterized and unspecialized cells that can grow and divide into many types, like muscle, blood, or organ cells. Stem cells serve as a repair mechanism, removing and replacing problematic cells and tissues by turning into the needed cells and reproducing.

Stem cell treatment promotes repair and growth of damaged, dysfunctional, or diseased tissues through the utilization of stem cells. Through this, stem cell therapy is often referred to as regenerative medicine. When done right, stem cell treatment enables the repair and healing of damaged organs.

However, stem cell treatment is not a cure-all. They are more common when dealing with problems in the muscles and bone marrows, where stem cells can routinely and reliably repair damages. But in specific organs, such as the pancreas and heart, stem cells can only reproduce under special conditions and circumstances. Stem cells are not panaceas; specific systems benefit more than others.

The basic idea in stem cell therapy for pets is the same as for humans. But because there are fewer medical regulations with animals than with humans, this regenerative process is used more with pets.

Pet stem cell therapy takes cells from the fat, bone marrow, umbilical cord, or blood of your pet or another animal with the same species, then injects them into the damaged area. The cells then get to work on the damages and cause new, healthy cells to grow, which will turn into unadulterated, healthy tissue.

Stem cell surgery is not for every pet, though. It will not magically cure the illness of your pet, and worse, it may cause adverse side effects. It is not for every budget bracket, either. Sessions can cost upwards of thousands of dollars, however, if it is for your pet care then it is worth it. Inquire a veterinarian about stem cell treatments and ask many inquiries about the procedure for pets.

Inflammation is caused by the immune systems response to foreign organisms. It is the bodys attempt at protecting itself by signaling the immune system to heal damages and defend from invaders. It is the same with dogs; inflammation is caused by the acting up of the immune system and the secretions of the white blood cells.

Stem cell treatments can be used to suppress or cure inflammation. Numerous studies cite the importance of Mesenchymal stem cells (MSCs) to counteract immune response and suppress inflammation for both humans and dogs.

In some instances, however, the immune system of both humans and animals dont work the way they were intended to be. Sometimes, the bodys defense response triggers an inflammation, even when there is nothing to fight off. These autoimmune diseases treat tissues as under attack of foreign invaders, even when there is no infection. Because of this, the bodys tissues are harmed.

In Pet Stem Cell Therapy, Adult Mesenchymal stem cells can be injected into affected joints. MSCs release anti-inflammatory enzymes that help relieve pain.

After ligament, tendon, or cartilage damage, the natural healing response takes over. But normal healing often results in scar formation and inferior tissue that fails to copy the original function, composition, and structure of the damaged part.

Regenerative healing suppresses inflammatory cells, and certain studies show that with Pet Stem Cell Therapy, MSCs improve tissue strength levels when compared to the still intact tissue.

Skeletal and muscle injuries are very common and may result from a wide variety of causes and mechanisms such as strains, lacerations, wounds, or over-exhaustion, which also affect dogs.

The transplanting of stem cells into the damaged or aberrant tissue is a central tenet of tissue engineering and regenerative medicine. Presently, the majority of reports treating skeletal and muscle injuries are limited mainly to animal experiments, and they produced positive results.

Degenerative diseases in dogs, such as degenerative myelopathy (a progressive condition in the spinal cord) and degenerative joint disease can be helped by pet stem cell therapy.

Owners report an improvement in mobility and range during the first few days and weeks of the procedure. Studies also show evidence in slowing the progression and the possible reversion of these rare, neurological diseases.

Pet stem cell therapy is mainly safe for your dogs, as the cells are harvested directly from your pet. However, stem cell treatments are looked down upon as cancer treatment because of its risk of causing cancer to worsen or spread more rapidly. Other than rest and support, minimal care is required for dogs after the procedure. Entrust your pet to a veterinarian with ample training and experience in regenerative medicine.

These are just some of the benefits of pet stem cell therapy. They can be successfully be used in a variety of treatments. However, research is still limited and the exact extent of avantages and even disadvantages is unknown. Like all treatments, Pet stem cell therapy also has side effects and limitations, it is best to do complete research and talk to an experianced vet who can guide you in the right decision. They will be better able to provide you the ifs and dont about how stem cell treatments can help your dog and their condition.

Read Out More Article5 Smart Reasons to Buy Pet Insurance Policy Now10 Cutest Dogs on Instagram12 Fictional Animal Sidekicks We Always Wanted But Cant Have

Follow this link:
Pet Stem Cell Therapy: How It Can Be A Life Saver For Your ...

The investigational DART protein MGD013, which targetd PD-1 and LAG-3, showed encouraging activity as a single agent as well as in combination with margetuximab as treatment of multiple tumor types in the MDG013 dose-escalation phase 1 study.

In the findinigs presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, partial response was observed in 3 patients, including 1 patient with gastric cancer and 1 patient with mesothelioma, both of whom had prior PD-1 therapy, as well as 1 patient with triple-negative breast cancer (TNBC) who was on therapy for more than 5 months. Additionally, 18 patients had stable disease as best overall response for a disease control rate of 48.8%.

Further, preliminary results in patients with relapsed/refractory HER2-positive solid tumors treated with MGD013 and margetuximab in the combination cohort had an overall response rate of 42.9% (6/14).

The rationale for dual targeting of PD-1 and LAG-3 stems from the observation that checkpoint molecules are leveraged by tumors or antigen presenting cells to evade the immune system, explained Jason J. Luke, MD, FACP, in a presentation. PD-1 and LAG-3 receptors are expressed on exhausted T-cells and interact with corresponding ligands in the gate anti-tumor activity.

Synergy of anti-PD-1 and anti-LAG-3 has been observed in preclinical models, explained Luke who is an associate professor of medicine in the Division of Hematology/Oncology and the director of the Cancer Immunotherapeutics Center within the University of Pittsburg Medical Center Hillman Cancer Immunology and Immunotherapy Program.

MGD013 is an investigational bispecific DART molecule that engages PD-1 and LAG-3 with a single molecule, resulting in greater T-cell activation than either a monoclonal antibody alone.

The phase 1 trial open-label, dose escalation and cohort expansion study (NCT03219268) was designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamics, and preliminary antitumor activity of MGD013 administered by IV infusion every 2 weeks. Another hypothesis investigators tested in the study was whether or not tumors can be made more responsive to PD-1 and LAG-3 intervention with the addition of an Fc-engineered monoclonal antibody, such as margetuximab.

In the initial dose-escalation cohort, patients were treated with MGD013 in a 3 + 3 design from 1 mg up to 1200 mg. Upon establishment of 600 mgs every 2 weeks as the recommended dose, monotherapy cohort expansions in ovarian, TNBC and nonsmall cell lung cancer (NSCLC), as well as multiple other tumor types including squamous cell carcinoma of the head and neck, small cell lung cancer, hepatocellular carcinoma, cholangiocarcinoma, cervical cancer, gastric/gastroesophageal junction carcinoma, and diffuse large B-cell lymphoma began enrolling patients.

In total, 53 patients participated in dose-escalation cohort; 205 patients participated in monotherapy cohort expansion; and 21 patients were treated in combination with margetuximab.

The 3 confirmed partial responses in the dose-escalation cohort each occurred at a different dose. The patient with TNBC had a response after treatment with a 10-mg dose; the patient with mesothelioma had a response with the 800-mg dose; and the patient with gastric cancer had a response with the 1200-mg dose.

The all-grade immune-related adverse events (AEs) of special interest observed in the dose-escalation cohort included rash (13.2%), hypothyroidism (11.3%), and immune-related hepatitis (3.8%). Grade 3 or higher AEs included immune-related hepatitis (3.8%), and 1 patient each reported respective cases of rash, pancreatitis, colitis, and adrenal insufficiency (1.9% each).

Youll note that broadly, [MGD013] was well tolerated with a manageable immune related adverse event profile and safety consistent with PD-1 or PD-L1 monotherapy in the treatment value setting, said Luke. Importantly, on-mechanism toxicities with immune-mediated hepatitis and lipase increase with radiographic evidence of pancreatitis were observed, though both resolved easily with steroids.

Anti-tumor activity was also observed in the MGD013 monotherapy cohort expansion across multiple tumor types including epithelial ovarian cancer (n = 23), TNBC (n = 23), and NSCLC, including both checkpoint inhibitor-nave (n = 14) and post PD-1 (n = 15). Confirmed partial response was observed in 2, 1, 2, and 0 patients, respectively. The overall response rates of both confirmed and unconfirmed partial responses were 8.7%, 4.3%, 21.4%, and 13.3%, respectively. Further, stable disease rates were 43.5%, 34.8%, 50.0%, and 53.3%.

The responses translated to a disease control rate of 52.2% in patients with epithelial ovarian cancer, 39.1% in patients with TNBC, 64.3% in patients with checkpoint inhibitor-nave NSCLC, and 53.3% in patients with NSCLC following PD-1 treatment.

Several cohorts are still ongoing, including a lymphoma cohort, Luke said. He cited a case from this cohort of a 27-year-old man with diffuse large B cell lymphoma who had progression of disease after chimeric antigen receptor (CAR) T-cell therapy who went on to receive 600-mg dose of MGD013. The patients pretreatment biopsy was noted for high expression of PD-1 and LAG-3 co-currently. Following the single dose of MGD013, the patient went on to be admitted on day 11 due to grade 2 cytokine release syndrome, but had a complete response on PET scanning at day 24 per Lugano criteria, Luke said. The patient went on to have allogeneic stem cell transplant and as of the presentation, was in remission 11 months post-MGD013 and 9 months post-transplant.

Given this early activity of MGD013 and these biomarker results, we are interested to more broadly analyze LAG-3 expression and more overall interferon expression as associated with treatment outcome, Luke said.

Reference

Luke JJ, Patel MR, Hamilton EP, et al. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD1 and LAG3, in patients with unresectable or metastatic neoplasms. J Clin Oncol. 2020;38(suppl 15; abstr 3004). doi:10.1200/JCO.2020.38.15_suppl.3004

See the rest here:
Encouraging Activity Observed With MGD013 In Various Tumor Types - Targeted Oncology

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare Current expenditure on health, % of gross domestic product Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs) Annual growth rate of current expenditure on health, per capita, in real terms Out-of-pocket expenditure, % of current expenditure on health Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs) Physicians, Density per 1000 population (head counts) Nurses, Density per 1000 population (head counts) Total hospital beds, per 1000 population Curative (acute) care beds, per 1000 population Medical technology, Magnetic Resonance Imaging units, total, per million population Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/2360

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Browse Full Report at https://www.xploremr.com/report/2360/canine-stem-cell-therapy-market

Standard Report Structure Executive Summary Market Definition Macro-economic analysis Parent Market Analysis Market Overview Forecast Factors Segmental Analysis and Forecast Regional Analysis Competition Analysis

Target Audience Production Companies Suppliers Channel Partners Marketing Authorities Subject Matter Experts Research Institutions Financial Institutions Market Consultants Government Authorities

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type: Allogeneic Stem Cells Autologous Stem cells

Application: Arthritis Dysplasia Tendonitis Lameness Others

End User: Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Region: North America Latin America Europe Asia Pacific Japan Middle East & Africa

Buy Full Report at https://www.xploremr.com/cart/2360/SL

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108

Here is the original post:
Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future - Cole of Duty